Loading market dashboard
Progyny, Inc.
PGNYHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Progyny delivers fertility benefits to major employers; a key insider recently trimmed their stake, according to SEC filings.
Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through available cash balances.
On May 21, 2026, Progyny Inc (PGNY) shares fell 3.8%, closing at $24.69. This decline comes amidst a 52-week range where the stock has seen a high of $28.75 and
Progyny, Inc. (PGNY) Shareholder/Analyst Call Transcript
For growth investors seeking exposure to a differentiated healthcare disruptor with strong secular tailwinds, Progyny (PGNY) stock deserves a close look.
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time.
Progyny NASDAQ: PGNY reported what management called a strong start to 2026, with first-quarter revenue reaching a record level and profitability exceeding expectations amid continued investments in its platform and member experience.
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Progyny (PGNY) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.48 per share a year ago.
Reports Record First Quarter Revenue of $328.5 MillionEarly Selling Season Activity Reflects Robust Demand for Women's Health and Family Building SolutionsReturned Value to Shareholders Through Repurchase of 8.8 Million Shares to Date Since November NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2026 (“the first quarter of 2026”), as compared to the three-month period ended March 31, 2025 (“the first quarter of 2025” or “the prior year period”). “We're pleased with the strong start to the year, as member engagement trended to the higher end of our expectations, reflecting that people are pursuing the services they need in order to address their family building and overall health and well-being goals,” said Pete Anevski, Chief Executive Officer of Progyny.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors with an interest in Medical Services stocks have likely encountered both Progyny (PGNY) and Alignment Healthcare (ALHC). But which of these two stocks is more attractive to value investors?
Progyny, Inc. (NASDAQ: PGNY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026.
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026.
NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announces Progyny Select, the industry's first fully insured, comprehensive supplemental fertility and family building plan. Available in the U.S., Progyny Select enables small employers to have access to fertility solutions in a fixed premium model.
On April 13, 2026, Progyny Inc (PGNY) shares rose 4.2% to a current price of $16.98. The stock has traded between $16.10 and $28.75 over the past 52 weeks, refl
Progyny (NASDAQ: PGNY - Get Free Report) and Surgery Partners (NASDAQ: SGRY - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a summary of current
Throughout 2026, in partnership with members, providers, and employers, Progyny will highlight a decade of innovation, expanded access, and industry-leading outcomes. Throughout 2026, in partnership with members, providers, and employers, Progyny will highlight a decade of innovation, expanded access, and industry-leading outcomes.
BG Medicine (OTCMKTS:BGMD - Get Free Report) and Progyny (NASDAQ: PGNY - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Earnings and Valuation This table compares BG Medicine and
Progyny (NASDAQ: PGNY - Get Free Report) and iSpecimen (NASDAQ: ISPC - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations. Profitability This table compares Progyny and iSpecimen's net margins,
ArrowMark Colorado Holdings LLC boosted its position in Progyny, Inc. (NASDAQ: PGNY) by 2.1% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,931,249 shares of the company's stock after purchasing an additional 39,666 shares during the quarter. ArrowMark Colorado
Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook.
